Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBsolvMIR in allogeneic islet transplantation for type 1 diabetes
NL-OMON54194Phase 2Completed
- Sponsor
- TikoMed
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ilb in diabetes mellitus type 1 (T1D) (2 arms), sponsored by TikoMed. Primary endpoint: Presence of adverse events. Started Jan 2024; status: completed.
02
Drugs
ilb
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on NL-OMON54194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54194.